Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,856
datasets available to search
ShareScore release 0.9.0
Dataset results
5,856 results for “B cells”
An Evaluation of LY007 Cell Injection for r/r B-NHL
ClinicalTrials.gov study NCT06364852. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
ClinicalTrials.gov study NCT04304040. IPD Sharing: NO. Countries: 1. Publications: 0.
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
ClinicalTrials.gov study NCT06854159. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
ClinicalTrials.gov study NCT05397496. IPD Sharing: NO. Countries: 9. Publications: 0.
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov study NCT00070083. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma
ClinicalTrials.gov study NCT01606605. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)
ClinicalTrials.gov study NCT00719472. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
ClinicalTrials.gov study NCT06144606. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell L
ClinicalTrials.gov study NCT06890884. IPD Sharing: YES. Countries: 9. Publications: 0.
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT05797948. IPD Sharing: YES. Countries: 1. Publications: 0.
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
ClinicalTrials.gov study NCT07066397. IPD Sharing: NO. Countries: 1. Publications: 0.
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
ClinicalTrials.gov study NCT00324779. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
ClinicalTrials.gov study NCT06853886. IPD Sharing: Not stated. Countries: 1. Publications: 0.
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
ClinicalTrials.gov study NCT04026100. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT06242834. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell
ClinicalTrials.gov study NCT05201248. IPD Sharing: YES. Countries: 1. Publications: 0.
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphom
ClinicalTrials.gov study NCT06047080. IPD Sharing: YES. Countries: 21. Publications: 0.
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov study NCT07200375. IPD Sharing: NO. Countries: 1. Publications: 0.
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT06536049. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA
ClinicalTrials.gov study NCT04763148. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.